- As China Slows Down, the Philippines Moves to Grab Foreign Investment
- Why Obamacare Subsidies Should Be Struck Down by the Supreme Court
- MannKind's Afrezza Earns Lackluster Review from Independent Drug Arbiter
- Shale Oil Bust Enters Phase Two, Led by Hercules and SandRidge
- Comcast Wants Congress to Gut the New Net Neutrality Rules
Jim Cramer explains why he likes everything he's hearing from Target's Brian Cornell.
We discuss why we're bullish on Halyard Health following the company's convincing earnings beat.
The expanded partnership should also provide a decent tailwind for MA's EPS growth.
We need some fear. Then we'll be ready to take out the highs.
We view the report as encouraging and reiterate our $60 price target.
Jim Cramer says the iconic US automaker is having the greatest year he can recall since its heyday.
CEO Cornell impresses communicating company strategy; buyback guidance clobbers even most bullish estimates.
We are not too concerned by the miss, as weather was likely a factor and pricing trends and mix are encouraging.
It's almost comical how welcoming it is these days.
One pivotal question is how quickly Target can resume buybacks.